You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Respiratory products

Please find a list of our respiratory products below.

Anoro Ellipta (umeclidinium / vilanterol inhalation powder)

Prescribing information

Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Incruse Ellipta (umeclidinium)

Prescribing information

Incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

Relvar Ellipta (fluticasone furoate/vilanterol inhalation powder)

Prescribing information

Asthma

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder and 184 micrograms/22 micrograms inhalation powder) is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Relvar Ellipta (92 micrograms/22 micrograms inhalation powder) is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

Incruse Ellipta and Relvar Ellipta (umeclidinium and fluticasone furoate / vilanterol inhalation powder)

Incruse in combination with Relvar for your COPD patients suitable for a LAMA + ICS/LABA.

Nucala (mepolizumab)

Prescribing information

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

Seretide 50/100, 50/250, 50/500 Accuhaler

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long- acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Note: Seretide 50 microgram /100 microgram strength is not appropriate in adults and children with severe asthma.

Chronic Obstructive Pulmonary Disease (COPD)

Seretide is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Seretide 25/50, 25/125, 25/250 Evohaler

Asthma

Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short- acting β2 agonist

or

  • patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Anoro, Incruse, Relvar, Nucala, Seretide, Ellipta, Flixotide, Serevent and Ventolin are
registered trademarks of the GlaxoSmithKline group of companies 

G.Y. Last updated: December 2016. UK/RESP/0485/15b(2)